Stocktoria
ASSEMBLY BIOSCIENCES, INC. ASMB
ASSEMBLY BIOSCIENCES, INC. (ASMB) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $72.3M at a -8.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.799 |
| Retained earnings / assets | -3.23 |
| EBIT / assets | -0.047 |
| Equity / liabilities | 4.067 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ASMB | ASSEMBLY BIOSCIENCES, INC. | 3/9 | -1.34 | — | +153.5% |
| BCYC | BICYCLE THERAPEUTICS PLC | 1/9 | 5.27 | — | +105.8% |
| VRDN | Viridian Therapeutics, Inc.DE | 2/9 | 2.72 | — | — |
| ABCL | AbCellera Biologics Inc. | 4/9 | 4.67 | — | +160.6% |
| RMTI | ROCKWELL MEDICAL, INC. | 2/9 | -18.33 | — | -31.8% |
| CTMX | CytomX Therapeutics, Inc. | 1/9 | -10.12 | — | -44.8% |
| KURA | Kura Oncology, Inc. | 2/9 | -2.37 | — | +25.2% |
About ASSEMBLY BIOSCIENCES, INC.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
FAQ
Is ASMB financially healthy?
ASSEMBLY BIOSCIENCES, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ASMB pay a dividend?
No, ASSEMBLY BIOSCIENCES, INC. does not currently pay a dividend.
How profitable is ASMB?
In FY2025, ASSEMBLY BIOSCIENCES, INC. had a net margin of -8.5% and a return on equity of -3.0%.
What is the analyst price target for ASMB?
The average Wall-Street price target for ASSEMBLY BIOSCIENCES, INC. is $50.00, about 84.8% above the recent price, from 4 analysts.
Is ASMB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ASSEMBLY BIOSCIENCES, INC.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.